Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
US Army
Harvard Business School
AstraZeneca
Moodys
Farmers Insurance
Cipla
Fish and Richardson
McKinsey
Federal Trade Commission

Generated: January 18, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,415,342

« Back to Dashboard

Summary for Patent: 8,415,342
Title:Besifloxacin ophthalmic composition for the treatment or control of infection
Abstract: A composition comprises besifloxacin in an amount effective for treating or controlling an infection caused by an antibiotic-resistant bacterium. Such a composition can be administered to a subject for the treatment or control of bacterial conjunctivitis caused bay an antibiotic-resistant bacterium.
Inventor(s): Tyle; Praveen (Pittsford, NY), Gupta; Pramod Kumar (Pittsford, NY), Norton; Susan E. (Rochester, NY), Brunner; Lynne (Webster, NY), Blondeau; Joseph (Saskatoon, CA)
Assignee: Bausch & Lomb Incorporated (Rochester, NY)
Application Number:12/604,422
Patent Claims: 1. A method for treating or controlling bacterial conjunctivitis in a human subject, the method comprising administering to said human subject a composition comprising besifloxacin at a concentration of 0.6% (weight by volume) at a frequency of two, three, or four times per day for 5-10 days in an amount effective for said treating or controlling, wherein said bacterial conjunctivitis is caused by a bacterium selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus warneri, Staphylococus hominis, Morganella morganii, Prevotella spp., and Fusobacterium against which an MIC.sub.90 of gatifloxacin or moxifloxacin is at least 4 .mu.g/mL.

2. The method of claim 1, wherein said bacterium is S. aureus or S. epidermidis resistant to both methicillin and ciprofloxacin.

3. A method for treating or controlling bacterial conjunctivitis in a human subject, the method comprising administering to said human subject a composition comprising besifloxacin at a concentration of 0.6% (weight by volume) at a frequency of two, three, or four times per day for 5-10 days in an amount effective for said treating or controlling, wherein said bacterial conjunctivitis is caused by a bacterium selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus warneri, Staphylococus hominis, Staphylococcus lugdunensis, and Morganella morganii against which an MIC.sub.90 of gatifloxacin or moxifloxacin is at least 4 .mu.g/mL, and an MIC.sub.90 of ciprofloxacin is greater than 8 .mu.g/mL.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
McKinsey
Moodys
Dow
Healthtrust
Johnson and Johnson
Boehringer Ingelheim
Cerilliant
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot